Target intelligence / Profile preview

Exoribonuclease 1 (ERI1)

Target
ERI1
Molecular classification
Enzyme, Exoribonuclease, DEDDh family, RNA metabolism enzyme
01

Overview

Exoribonuclease 1 (ERI1) is an evolutionarily conserved 3'-5' exoribonuclease of the DEDDh family that catalyzes the trimming of 3' overhangs in structured RNA substrates, most notably the 3' ends of histone mRNAs and 5.8S ribosomal RNA, and also regulates small RNA turnover such as siRNA and microRNA. It is involved in both the maturation of ribosomal RNA and the regulated degradation of histone mRNAs following DNA replication, contributing to gene silencing, chromatin regulation, and proper cell-cycle progression. ERI1 also modulates RNA interference pathways, limiting or fine-tuning siRNA responses in multiple organisms. Dysregulation or mutation of ERI1 is associated with human genetic diseases (such as spondyloepimetaphyseal dysplasia), but no drug interactions or direct cancer links are well described at present.

Other names
3'-5' exoribonuclease 13'EXOTHEX1HEXO3'HEXO3'-5' exonuclease ERI1Eri-1 homologHistone mRNA 3'-end-specific exoribonucleaseHistone mRNA 3'-exonuclease 1Protein 3'hExoHXALSEMDGCSEMDGSthree prime histone mRNA exonuclease 1three prime mRNA exonuclease 1
02

Mechanism of action

3'-5' exoribonucleolytic degradation of RNA substrates (e.g., histone mRNAs, siRNAs, 5.8S rRNA)

03

Biological functions

5.8S rRNA 3'-end processingHistone mRNA degradationSmall RNA turnover (especially siRNA and microRNA)Regulation of RNA interferenceChromatin-associated siRNA turnoverEpigenetic gene regulation
04

Disease associations

Spondyloepimetaphyseal dysplasia, Guo-Campeau typeHoxha-Aliu syndromepossible roles in chondrogenesis and epigenetic regulationno well-documented direct roles in cancer, infection, etc.
05

Safety considerations

No established small-molecule inhibitors or drugsessential for RNA homeostasis and cell viability, thus inhibition may disrupt ribosome biogenesis and histone mRNA turnover, potentially causing broad cellular dysfunction

Beyond the preview

Go deeper on Exoribonuclease 1 (ERI1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Exoribonuclease 1 (ERI1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call